Aviva PLC Has $117.05 Million Position in Boston Scientific Corporation $BSX

Aviva PLC lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 59.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,089,699 shares of the medical equipment provider’s stock after purchasing an additional 406,753 shares during the period. Aviva PLC’s holdings in Boston Scientific were worth $117,045,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Riverwater Partners LLC boosted its stake in shares of Boston Scientific by 3.3% in the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after purchasing an additional 98 shares during the last quarter. IVC Wealth Advisors LLC grew its holdings in Boston Scientific by 4.9% during the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after acquiring an additional 102 shares during the period. Park Square Financial Group LLC raised its position in shares of Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock valued at $208,000 after acquiring an additional 103 shares during the last quarter. HHM Wealth Advisors LLC lifted its stake in shares of Boston Scientific by 13.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 103 shares during the period. Finally, Rise Advisors LLC boosted its position in shares of Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 103 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,782 shares of company stock worth $17,742,314 over the last ninety days. 0.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a report on Monday, September 29th. Barclays boosted their target price on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Robert W. Baird increased their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Morgan Stanley boosted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Truist Financial upped their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Price Performance

NYSE BSX opened at $100.05 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market cap of $148.26 billion, a price-to-earnings ratio of 53.50, a PEG ratio of 2.02 and a beta of 0.58. The business has a 50 day simple moving average of $100.09 and a 200 day simple moving average of $102.45. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s revenue was up 20.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.